retina expansion Capitalize on Lexitas recent retina focused acquisitions and leadership additions to offer end-to-end retina research capabilities, imaging analysis, and reading center support to pharma and device sponsors seeking expanded ophthalmic trial footprints.

strategic collaborations Leverage the NAMSA partnership to position Lexitas as a preferred partner for end-to-end ophthalmic medical device development in Ohio and North Carolina, targeting sponsors requiring integrated regulatory, design, and clinical execution.

groundbreaking studies Highlight ongoing multicenter pilot with Ocusun evaluating ZOC2017217 to demonstrate capability in delivering multicenter, first-in-class ophthalmic therapies, and use this as a proof point to win similar early- and late-stage ophthalmology programs.

clinical breadth Promote Lexitas’s deep expertise across anterior and posterior segment diseases and rare conditions, offering tailored study design, endpoint evaluation, reading center, and biostatistics to attract sponsors with complex ophthalmic endpoints.

growth signals Emphasize the company’s mid-market revenue scale and focused ophthalmology domain to target mid-sized sponsors dissatisfied with generic CROs, presenting a compelling value proposition with specialized scientific leadership and faster, high-quality trial delivery.